GlassScriptPhysician profile
Kasey Murphy
NPI 1407246853
$3,066.94
in general payments reported to CMS, 2019-2025
28 companies · $36.55 in 2025
The $36.55 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,035 · 2022: $1,019 · 2023: $976 · 2025: $36.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.73 | 2021-2023 | |
| Novo Nordisk INC | $411.45 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.14 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $251.36 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $186.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $182.35 | 2021-2022 | |
| Amgen INC. | $128.92 | 2021-2023 | Otezla, Repatha |
| Lilly USA, LLC | $87.45 | 2021-2023 | Mounjaro, Jardiance, Trulicity |
| Exact Sciences Corporation | $73.18 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $68.78 | 2022-2023 | Abilify Maintena, Rexulti |
| Glaxosmithkline, LLC. | $63.26 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $60.00 | 2023 | Sunosi, Auvelity |
| Pfizer INC. | $59.12 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.10 | 2021-2023 | Xifaxan |
| Insulet Corporation | $40.08 | 2023 | Omnipod |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.96 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.59 | 2021 | |
| Astellas Pharma US INC | $25.12 | 2022-2023 | Myrbetriq |
| Corium, LLC | $23.37 | 2022 | |
| Alkermes, INC. | $17.88 | 2023 | Lybalvi |
| Neurocrine Biosciences, INC. | $16.58 | 2022 | |
| Allergan, INC. | $15.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.76 | 2021 | |
| Merck Sharp & Dohme LLC | $14.39 | 2023 | Verquvo, Belsomra |
| Lundbeck LLC | $13.55 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $13.39 | 2022 | |
| Adlon Therapeutics L.P. | $11.36 | 2021 | |
| Abbott Laboratories | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasey Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.